Linked Life Data

15717653

Source:http://linkedlifedata.com/resource/pubmed/id/15717653

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2005-2-18
pubmed:abstractText
Activating point mutations of RET gene have been demonstrated to be causative of the familial form of medullary thyroid cancer (MTC), both isolated (FMTC) and associated to other endocrine neoplasia [multiple endocrine neoplasia (MEN) 2A and 2B]. In RET gene mutation carriers, who are prone to developing MTC, prophylactic thyroidectomy is recommended to obtain their definitive cure. The simultaneous excision of the central node compartment is mandatory when the stimulation pentagastrin test for serum calcitonin is positive. Although the minimally invasive video assisted thyroidectomy (MIVAT) is nowadays currently adopted in many centers, it has never been employed for the prophylactic thyroidectomy of RET gene mutation carriers. The fear of obtaining an incomplete lymphadenectomy of the central compartment was the main reason for this reluctance. Since RET gene mutation carriers have often normal thyroid volume and, if involved, small lymph nodes, they indeed represent the best candidates to this approach especially when considering that they are usually young and concerned about the cosmetic results and the period of hospitalization. The excellent results obtained by MIVAT in the last few years induced us to propose this procedure together with a central compartment lymphadenectomy to 2 RET gene mutation carriers recently found by genetic screening. As assessed by a negative pentagastrin stimulation test performed after 6 months from the MIVAT, they were definitively cured without any surgical complication with the exception of a transient hypoparathyroidism. They showed a great satisfaction for both the cosmetic results and the very short period of hospitalization, thus supporting the idea that MIVAT can be used in association with the central node dissection for the prophylactic treatment of RET mutation gene carriers whose thyroid volume is still normal.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0391-4097
pubmed:author
pubmed:issnType
Print
pubmed:volume
27
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
557-61
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed-meshheading:15717653-Adult, pubmed-meshheading:15717653-Carcinoma, Medullary, pubmed-meshheading:15717653-Female, pubmed-meshheading:15717653-Genetic Predisposition to Disease, pubmed-meshheading:15717653-Genetic Testing, pubmed-meshheading:15717653-Humans, pubmed-meshheading:15717653-Hypoparathyroidism, pubmed-meshheading:15717653-Lymph Node Excision, pubmed-meshheading:15717653-Male, pubmed-meshheading:15717653-Middle Aged, pubmed-meshheading:15717653-Oncogene Proteins, pubmed-meshheading:15717653-Point Mutation, pubmed-meshheading:15717653-Proto-Oncogene Proteins c-ret, pubmed-meshheading:15717653-Receptor Protein-Tyrosine Kinases, pubmed-meshheading:15717653-Siblings, pubmed-meshheading:15717653-Thyroid Neoplasms, pubmed-meshheading:15717653-Thyroidectomy, pubmed-meshheading:15717653-Video-Assisted Surgery
pubmed:year
2004
pubmed:articleTitle
Video assisted prophylactic thyroidectomy and central compartment nodes clearance in two RET gene mutation adult carriers.
pubmed:affiliation
Department of Surgery, University of Pisa, Pisa, Italy. p.miccoli@dc.med.unipi.it
pubmed:publicationType
Journal Article, Case Reports, Research Support, Non-U.S. Gov't